Intraperitoneal Local Anaesthetic in Colonic Surgery
|ClinicalTrials.gov Identifier: NCT00722709|
Recruitment Status : Completed
First Posted : July 25, 2008
Last Update Posted : January 13, 2010
The general aim of this research group is to improve the recovery of patients after abdominal surgery. The specific aim of this study is to conduct a randomized, double blinded, controlled trial to investigate the effect of intra-peritoneal local anaesthesia application on postoperative pain and post-operative fatigue. This will be conducted in the setting of an enhanced recovery after surgery program (ERAS).
Patients will be randomised by computer generated random numbers and opaque envelope method. In the treatment arm patients will receive 10ml 0.75% ropivacaine diluted to 50mls with 0.9% saline soon after the creation of the laparotomy . In the placebo arm, 50mls of 0.9% normal saline will be used in a similar fashion. At closure, two small 2mm catheter belonging to the On-Q pain buster system will be placed in the peritoneal cavity. This will be attached to a pump which will contain either a 0.2% ropivacaine solution or 0.9% saline placebo running at 4mls/hr for 68 hours. All members involved in patient care (with the exception of one nurse) will be blinded to the above. After 68 hours the pump will be stopped and the catheter will be removed. Assessment of postoperative pain will be performed by visual analogue scale, and fatigue assessment will be done using the Identity Consequence Fatigue Scale (ICFS) at various intervals post-operatively. Blood tests for inflammatory markers including glucose, cortisol, CRP, albumin and several cytokines as well as local anaesthetic levels will be taken.
Significance to health:
This method of analgesia administration has not been investigated in open major colonic surgery. This trial has wide reaching implications, with the potential to improve pain and thus recovery after abdominal surgery.
|Condition or disease||Intervention/treatment||Phase|
|Colon Surgery||Drug: Ropivacaine Drug: 0.9% Saline||Phase 1|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Randomised Double Blind Trial to Investigate the Effects of Intraperitoneal Local Anaesthetic Following Colonic Surgery.|
|Study Start Date :||September 2008|
|Primary Completion Date :||November 2009|
|Study Completion Date :||January 2010|
Use of Ropivacaine
In the treatment arm patients will receive 10mls 0.75% ropivacaine diluted to 50mls with saline immediately before closure.
At closure, two small 2 mm catheters will be placed in the peritoneal cavity at the site of the operation to infuse local anaesthesia. This will penetrate through the skin once closure is complete. This will be attached to a small infusion pump (On-Q pain buster). This pump will contain 270mls of 0.2% ropivacaine. After 68 hours the pump will be stopped and the catheter will be removed in a similar fashion as routine drain removal.
Placebo Comparator: Placebo
Use of 0.9% saline
Drug: 0.9% Saline
In the placebo arm patients will receive 50 ml 0.9% saline into the peritoneum soon after the creation of the laparotomy.
At closure, two 2 mm catheters will be placed in the peritoneal cavity at the site of the operation to infuse local anaesthesia. This will penetrate through the skin once closure is complete. This will be attached to a small infusion pump on-Q pain buster). This pump will contain 0.9% saline. After 68 hours the pump will be stopped and the catheter will be removed in a similar fashion as routine drain removal.
- Post operative recovery using the Identity consequence fatigue scale (ICFS) [ Time Frame: Base-line, Day 1, Day 3, Day 7, Day 14, Day 30, Day 60 ]
- Post-operative rest, movement and cough pain using Visual analogue score [ Time Frame: 2,4,6,8,12,24,48,72 hours and on day 7 ]
- Post operative analgesia use using morphine equivalence data [ Time Frame: Total use on day 1, day 2, day 3 post operatively and total use until discharge ]
- Serum Ropivacaine level, serum Cytokine, serum Cortisol, serum glucose and serum CRP. Albumin, haematological parameters and biochemical parameters. [ Time Frame: Pre-operatively, 8, 20, 48,72 hours post operatively ]
- Questions aimed at symptoms of local anaesthetic toxicity [ Time Frame: 2, 4, 6, 8, 12, 24, 48, 72 hours post operatively ]
- Recovery of bowel function measured by time to pass flatus and time to pass stool post-operatively. [ Time Frame: Assessed at 2, 4, 6, 8, 12, 24, 36, 48, 60, 72 hours. ]
- Quality of care assessment based on a 100mm visual analogue scale (1-10). [ Time Frame: pre-op, day1, day 2, day3, day 7, day 30 and day 60 post operatively ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00722709
|Manukau Surgery Centre-Middlemore Hospital|
|Auckland, New Zealand, 2240|
|University of Auckland|
|Auckland, New Zealand|
|Study Director:||Arman A Kahokehr, MBChB||University of Auckland, New Zealand|
|Principal Investigator:||Andrew G Hill, FRACS||University of Auckland, New Zealand|